Review summary
Teaching objective: Recognize primary adrenal insufficiency in a 40-year-old writer whose tiredness, weight loss, nausea, back ache and darkening skin could be put down to overwork or low mood, and care for it on the Endocrine Society 2016 guideline: low sodium, high potassium and raised eosinophils as clues; urgent testing with an 8 am cortisol and ACTH and a cosyntropin stimulation test, without delaying treatment if she becomes unstable; renin and aldosterone for mineralocorticoid deficiency; 21-hydroxylase antibodies for the cause, with adrenal imaging and tuberculosis testing only if they are negative; lymphoma kept in the differential (examination for nodes and spleen, LDH, chest X-ray, and weight and symptoms on treatment) because a retrospective diagnosis of her real illness proposes it; hydrocortisone in two daily doses and fludrocortisone adjusted by blood pressure lying and standing, electrolytes and renin; written sick-day rules, an emergency injection kit, a steroid card and a medical ID, then used in a febrile illness; screening for associated autoimmune disease; anemia work-up (CMID anemia monograph); and listening to the patient's own written account of her illness. Her real illness remains undiagnosed; this record shows one modern possibility, not an answer.
Historical timeline
| Date | Event | Claims |
|---|---|---|
| December 16, 1775 | Born at Steventon Rectory, Hampshire. | CLM-0001 |
| 1783 | Putrid fever at school in Southampton; nearly died. | CLM-0004 |
| January 21, 1805 | Death of her father after an illness of forty-eight hours. | CLM-0020 |
| 1809 | Moved to Chawton with her mother and sister; neither sister married. | CLM-0002, CLM-0003 |
| March 1816 | Her health began to break. | CLM-0005 |
| May 1816 | Three weeks at Cheltenham; visibly out of health. | CLM-0006 |
| July 18, 1816 | First draft of Persuasion finished. | CLM-0007 |
| September 8, 1816 | Letter on back pain, agitation and fatigue. | CLM-0008 |
| February 20, 1817 | Letter on rheumatism. | CLM-0009 |
| March 23, 1817 | Letter on fever and her colour. | CLM-0010 |
| April 6, 1817 | Letter on a bilious attack with fever; confined upstairs; seen pale and weak by her niece. | CLM-0011, CLM-0012 |
| July 18, 1817 | Died at Winchester; buried in Winchester Cathedral. | CLM-0013 |
| 1964 | Cope proposes Addison's disease. | CLM-0015 |
| 2005 | Upfal proposes Hodgkin's disease. | CLM-0016 |
| 2009 | White proposes disseminated bovine tuberculosis. | CLM-0017 |
| 2017 | British Library post on cataracts and the arsenic theory. | CLM-0019 |
| 2021 | Sanders and Graham propose systemic lupus erythematosus; the society biography gives Addison's disease as possible. | CLM-0014, CLM-0018 |
Evidence claims
D = documented, R = retrospective, S = synthetic.
| Grade | Claim | Certainty | Sources |
|---|---|---|---|
| D | Jane Austen was born at the Rectory in Steventon, a village in north-east Hampshire, on 16 December 1775, the seventh child and second daughter of the rector, the Revd George Austen, and his wife Cassandra (née Leigh). | confirmed | Jane Austen: A brief biography supports HISTMED Master Roster v3 context |
| D | Steventon Rectory was her home for the first 25 years of her life; after some years in Bath and Southampton she moved in 1809 with her mother and sister to a cottage at Chawton, on one of her brother Edward's Hampshire estates, where she revised her early novels and wrote Mansfield Park, Emma and Persuasion. Anchors the modern home and work history. |
confirmed | Jane Austen: A brief biography supports |
| D | Her only sister, Cassandra, like Jane herself, never married. Anchors the modern social history; she has no children. |
confirmed | Jane Austen: A brief biography supports |
| D | In 1783, as a young child at school in Southampton with her sister, she caught a putrid fever and was very ill and nearly died. Past history only; not used as a modern diagnosis. |
probable | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| D | The chronology in the 1913 family biography dates the first break in her health to about March 1816. The anchor for the index visit and the synthetic presenting illness. |
probable | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| D | In May 1816 she and Cassandra spent three weeks at Cheltenham, stopping at Steventon and at Kintbury on the way; the family biographers judged that she 'must have been decidedly out of health, for the change in her did not escape the notice of her friends.' After the index date. No modern visit is placed in May or June. |
probable | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| D | She wrote 'Finis' at the end of the first draft of Persuasion on 18 July 1816; the family memoir quoted in the 1913 biography speaks of the weak state of her health at the time. After the index date; recorded as history. |
confirmed | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| D | In a letter to Cassandra on 8 September 1816 she wrote: 'Thank you, my back has given me scarcely any pain for many days. I have an idea that agitation does it as much harm as fatigue, and that I was ill at the time of your going from the very circumstance of your going.' After the index date; her own account of back pain and fatigue, echoed in the synthetic presenting symptoms. |
confirmed | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports Coolidge S (ed.). The Letters of Jane Austen, selected from the Brabourne edition (1892), Project Gutenberg eBook 42078 supports |
| D | On 20 February 1817 she wrote to her niece Fanny Knight that she was 'almost entirely cured of my rheumatism—just a little pain in my knee, now and then'. After the index date; recorded as history. |
confirmed | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| D | On 23 March 1817 she wrote to Fanny Knight: 'I certainly have not been well for many weeks, and about a week ago I was very poorly. I have had a good deal of fever at times, and indifferent nights; but I am considerably better now and am recovering my looks a little, which have been bad enough—black and white and every wrong colour.' After the index date; her own description of her colour, on which the Addison's disease interpretation rests. |
confirmed | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports Coolidge S (ed.). The Letters of Jane Austen, selected from the Brabourne edition (1892), Project Gutenberg eBook 42078 supports Sanders MD, Graham EM. 'Black and white and every wrong colour': the medical history of Jane Austen and the possibility of systemic lupus erythematosus. Lupus. 2021;30(6) (PMID 33596714) context |
| D | On 6 April 1817 she wrote to her brother Charles that she had been 'suffering from a bilious attack attended with a good deal of fever', that she lived upstairs for the present, and that she was not strong enough to travel except in a closed carriage. After the index date; recorded as history. |
confirmed | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| D | Her niece Caroline, who saw her in the spring of 1817, recalled that she was very pale, her voice weak and low, with 'a general appearance of debility and suffering', and had been told that she never had much acute pain. After the index date; recorded as history. |
confirmed | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| D | On 24 May 1817 she moved to Winchester to be under the care of Mr. Lyford; she died there on 18 July 1817 at lodgings at No. 8 College Street, and was buried a few days later in the north aisle of Winchester Cathedral. History only; not used in the modern episode. |
confirmed | Jane Austen: A brief biography supports Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
| R | The Jane Austen Society's biography says she fell ill in 1816, possibly with Addison's disease. Retrospective interpretation; the modern episode makes this diagnosis as synthetic content, not as a claim about her. |
possible | Jane Austen: A brief biography supports |
| R | In 1964 the surgeon Sir Zachary Cope proposed in the British Medical Journal that her final illness was Addison's disease, which in his time was usually tuberculous; he relied heavily on her description of her colouring. Retrospective interpretation, disputed by later authors. |
disputed | Cope Z. Jane Austen's last illness. Br Med J. 1964;2(5402):182-183 (PMID 14150900, PMC1816080) supports Upfal A. Jane Austen's lifelong health problems and final illness: new evidence points to a fatal Hodgkin's disease and excludes the widely accepted Addison's. Med Humanit. 2005;31(1):3-11 (PMID 23674643) supports White KG. Jane Austen and Addison's disease: an unconvincing diagnosis. Med Humanit. 2009;35(2) (PMID 23674705) supports |
| R | Annette Upfal argued in 2005 that the evidence tends to exclude Addison's disease and that her fatal illness was quite possibly Hodgkin's disease, a lymphoma, with an immune deficiency perhaps present by January 1813; she also noted that Cassandra destroyed letters containing medical detail and that the cause cannot now be established conclusively. Retrospective interpretation; the reason the modern consultant keeps lymphoma in the differential until it is excluded. |
disputed | Upfal A. Jane Austen's lifelong health problems and final illness: new evidence points to a fatal Hodgkin's disease and excludes the widely accepted Addison's. Med Humanit. 2005;31(1):3-11 (PMID 23674643) supports |
| R | Katherine White argued in 2009 that symptoms reported by Addison's patients of the period (mental confusion, generalised pain, weight loss and anorexia) are absent from her letters, so Addison's disease is unlikely, and that disseminated bovine tuberculosis would explain her symptoms coherently. Retrospective interpretation; the reason tuberculosis is considered as a cause until the antibody result is known. |
disputed | White KG. Jane Austen and Addison's disease: an unconvincing diagnosis. Med Humanit. 2009;35(2) (PMID 23674705) supports |
| R | Sanders and Graham argued in 2021 that the rheumatism, facial skin changes, fever and fluctuating symptoms in her letters fulfil current classification criteria for systemic lupus erythematosus. Retrospective interpretation; not used in the modern episode. |
possible | Sanders MD, Graham EM. 'Black and white and every wrong colour': the medical history of Jane Austen and the possibility of systemic lupus erythematosus. Lupus. 2021;30(6) (PMID 33596714) supports |
| R | A British Library curator noted in 2017 that her early death has been attributed to Addison's disease, cancer and tuberculosis, and that in 2011 a crime writer suggested arsenic poisoning on the basis of her facial pigmentation; the curator presented cataracts, possibly from arsenic, only as a theory raised by her spectacles. Retrospective speculation; not used in the modern episode. |
disputed | Tuppen S. Did Jane Austen develop cataracts from arsenic poisoning? supports |
| D | Her father died on 21 January 1805 after an illness of only forty-eight hours. Family history; the cause is not recorded in the cited source. |
confirmed | Austen-Leigh W, Austen-Leigh RA. Jane Austen, Her Life and Letters: A Family Record (1913), Project Gutenberg eBook 22536 supports |
Modern synthetic problem list
| Grade | Problem | Clinical status | Verification | Placement | Historical claims |
|---|---|---|---|---|---|
| S | About three months of increasing tiredness, loss of 5 kg, darkening of the skin, nausea with bouts of vomiting, low back ache, salt craving and lightheadedness on standing, with low sodium, high potassium and raised eosinophils; adrenal insufficiency suspected and urgent endocrinology testing booked | resolved | confirmed | active | CLM-0005 |
| S | Primary adrenal insufficiency (Addison's disease): no cortisol response to cosyntropin with a markedly raised ACTH, and mineralocorticoid deficiency with raised renin and low aldosterone; on hydrocortisone and fludrocortisone; synthetic modern diagnosis chosen for a historical illness whose cause is disputed | active | confirmed | both_with_link | CLM-0014, CLM-0015 |
| S | Mild normocytic anemia (hemoglobin 11.4 g/dL) with normal ferritin, vitamin B12 and folate | resolved | confirmed | active | |
| S | Group A streptococcal pharyngitis with fever, treated with amoxicillin and doubled hydrocortisone under the sick-day rules; resolved | resolved | confirmed | active |
Synthetic outcome measures
| Grade | Date | Measure | Result | Coding |
|---|---|---|---|---|
| S | 2026-03-16 | Hemoglobin [Mass/volume] in Blood | 11.4 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-03-16 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 89 fL Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 2026-03-16 | Leukocytes [#/volume] in Blood by Automated count | 5.8 10*3/uL Reference 4-11 10*3/uL |
http://loinc.org · 6690-2 |
| S | 2026-03-16 | Eosinophils [#/volume] in Blood | 0.74 10*3/uL (high) Reference 0-0.5 10*3/uL |
http://loinc.org · 26449-9 |
| S | 2026-03-16 | Platelets [#/volume] in Blood by Automated count | 262 10*3/uL Reference 150-400 10*3/uL |
http://loinc.org · 777-3 |
| S | 2026-03-16 | Sodium [Moles/volume] in Serum or Plasma | 131 mmol/L (low) Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-16 | Potassium [Moles/volume] in Serum or Plasma | 5.4 mmol/L (high) Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-03-16 | Chloride [Moles/volume] in Serum or Plasma | 99 mmol/L Reference 98-107 mmol/L |
http://loinc.org · 2075-0 |
| S | 2026-03-16 | Carbon dioxide, total [Moles/volume] in Serum or Plasma | 21 mmol/L (low) Reference 22-29 mmol/L |
http://loinc.org · 2028-9 |
| S | 2026-03-16 | Urea nitrogen [Mass/volume] in Serum or Plasma | 23 mg/dL (high) Reference 7-20 mg/dL |
http://loinc.org · 3094-0 |
| S | 2026-03-16 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 mg/dL Reference 0.57-1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-03-16 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 79 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-03-16 | Glucose [Mass/volume] in Serum or Plasma | 72 mg/dL Reference 70-139 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-03-16 | Calcium [Mass/volume] in Serum or Plasma | 10.1 mg/dL Reference 8.6-10.3 mg/dL |
http://loinc.org · 17861-6 |
| S | 2026-03-16 | Thyrotropin [Units/volume] in Serum or Plasma | 3.6 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-03-16 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 ng/dL Reference 0.8-1.8 ng/dL |
http://loinc.org · 3024-7 |
| S | 2026-03-16 | Ferritin [Mass/volume] in Serum or Plasma | 64 ng/mL Reference 15-150 ng/mL |
http://loinc.org · 2276-4 |
| S | 2026-03-16 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 486 pg/mL Reference 232-1245 pg/mL |
http://loinc.org · 2132-9 |
| S | 2026-03-16 | Folate [Mass/volume] in Serum or Plasma | 11.2 ng/mL Reference Above 5.9 ng/mL: normal |
http://loinc.org · 2284-8 |
| S | 2026-03-16 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | http://loinc.org · 44261-6 |
| S | 2026-03-19 | Cortisol [Mass/volume] in Serum or Plasma | 2.6 ug/dL (low) Reference 8 am: 5 to 23 ug/dL |
http://loinc.org · 2143-6 |
| S | 2026-03-19 | Corticotropin [Mass/volume] in Plasma | 548 pg/mL (high) Reference 7.2-63 pg/mL |
http://loinc.org · 2141-0 |
| S | 2026-03-19 | Cortisol [Mass/volume] in Serum or Plasma --30 minutes post 250 ug corticotropin IV rapid | 3.4 ug/dL (low) Reference Peak of 18 ug/dL or more excludes adrenal insufficiency (about 14 to 15 ug/dL on newer assays) |
http://loinc.org · 1417-5 |
| S | 2026-03-19 | Cortisol [Mass/volume] in Serum or Plasma --1 hour post 250 ug corticotropin IV rapid | 3.9 ug/dL (low) Reference Peak of 18 ug/dL or more excludes adrenal insufficiency (about 14 to 15 ug/dL on newer assays) |
http://loinc.org · 1402-7 |
| S | 2026-03-19 | Renin [Enzymatic activity/volume] in Plasma | 16.2 ng/mL/h (high) Reference Upright, mid-morning: 0.6 to 4.3 ng/mL/h |
http://loinc.org · 2915-7 |
| S | 2026-03-19 | Aldosterone [Mass/volume] in Serum or Plasma | 1.8 ng/dL (low) Reference Upright, mid-morning: 4 to 31 ng/dL |
http://loinc.org · 1763-2 |
| S | 2026-03-19 | Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma | 172 U/L Reference 140-280 U/L |
http://loinc.org · 2532-0 |
| S | 2026-03-19 | Sodium [Moles/volume] in Serum or Plasma | 132 mmol/L (low) Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-03-19 | Potassium [Moles/volume] in Serum or Plasma | 5.3 mmol/L (high) Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-02 | Sodium [Moles/volume] in Serum or Plasma | 137 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-02 | Potassium [Moles/volume] in Serum or Plasma | 4.6 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-02 | Creatinine [Mass/volume] in Serum or Plasma | 0.86 mg/dL Reference 0.57-1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-02 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 88 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-02 | Glucose [Mass/volume] in Serum or Plasma | 88 mg/dL Reference 70-139 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-04-02 | Hemoglobin [Mass/volume] in Blood | 11.9 g/dL (low) Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-02 | Eosinophils [#/volume] in Blood | 0.38 10*3/uL Reference 0-0.5 10*3/uL |
http://loinc.org · 26449-9 |
| S | 2026-04-30 | Sodium [Moles/volume] in Serum or Plasma | 139 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-30 | Potassium [Moles/volume] in Serum or Plasma | 4.4 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-30 | Creatinine [Mass/volume] in Serum or Plasma | 0.84 mg/dL Reference 0.57-1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-04-30 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 90 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-04-30 | Renin [Enzymatic activity/volume] in Plasma | 3.4 ng/mL/h Reference Upright, mid-morning: 0.6 to 4.3 ng/mL/h |
http://loinc.org · 2915-7 |
| S | 2026-04-30 | Hemoglobin [Mass/volume] in Blood | 12.6 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-04-30 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 90 fL Reference 80-100 fL |
http://loinc.org · 787-2 |
| S | 2026-10-12 | Sodium [Moles/volume] in Serum or Plasma | 140 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-10-12 | Potassium [Moles/volume] in Serum or Plasma | 4.2 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-10-12 | Creatinine [Mass/volume] in Serum or Plasma | 0.85 mg/dL Reference 0.57-1 mg/dL |
http://loinc.org · 2160-0 |
| S | 2026-10-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 89 mL/min/1.73 m² Reference >=60 mL/min/1.73 m² |
http://loinc.org · 98979-8 |
| S | 2026-10-12 | Renin [Enzymatic activity/volume] in Plasma | 2.8 ng/mL/h Reference Upright, mid-morning: 0.6 to 4.3 ng/mL/h |
http://loinc.org · 2915-7 |
| S | 2026-10-12 | Hemoglobin [Mass/volume] in Blood | 13.2 g/dL Reference 12-15.5 g/dL |
http://loinc.org · 718-7 |
| S | 2026-10-12 | Thyrotropin [Units/volume] in Serum or Plasma | 2.9 mIU/L Reference 0.45-4.5 mIU/L |
http://loinc.org · 3016-3 |
| S | 2026-10-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | http://loinc.org · 44261-6 |
| S | 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 136 mmol/L Reference 135-145 mmol/L |
http://loinc.org · 2951-2 |
| S | 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4.7 mmol/L Reference 3.5-5.1 mmol/L |
http://loinc.org · 2823-3 |
| S | 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 91 mg/dL Reference 70-139 mg/dL |
http://loinc.org · 2345-7 |
| S | 2026-07-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | http://loinc.org · 55758-7 |
| S | 2026-07-27 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 2 | http://loinc.org · 70274-6 |
| S | 2026-07-27 | Total score [AUDIT-C] | 1 | http://loinc.org · 75626-2 |
| S | 2026-07-27 | Cholesterol [Mass/volume] in Serum or Plasma | 182 mg/dL Reference <=199 mg/dL |
http://loinc.org · 2093-3 |
| S | 2026-07-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 68 mg/dL Reference >=50 mg/dL |
http://loinc.org · 2085-9 |
| S | 2026-07-27 | Triglyceride [Mass/volume] in Serum or Plasma | 74 mg/dL Reference <=149 mg/dL |
http://loinc.org · 2571-8 |
| S | 2026-07-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 99 mg/dL Reference <=99 mg/dL |
http://loinc.org · 13457-7 |
| S | 2026-04-02 | 21-Hydroxylase Ab [Units/volume] in Serum | 24 U/mL (high) Reference Below 1 U/mL: negative |
http://loinc.org · 17781-6 |
| S | 2026-04-02 | Hemoglobin A1c/Hemoglobin.total in Blood | 5% Reference Below 5.7% is normal; 5.7 to 6.4% prediabetes |
http://loinc.org · 4548-4 |
| S | 2026-04-02 | Tissue transglutaminase IgA Ab [Units/volume] in Serum | 0.8 U/mL Reference Below 4 U/mL: negative |
http://loinc.org · 31017-7 |
| S | 2026-04-02 | IgA [Mass/volume] in Serum or Plasma | 188 mg/dL Reference 70-400 mg/dL |
http://loinc.org · 2458-8 |
Synthetic vital signs
| Date | Measure | Result | LOINC | Grade |
|---|---|---|---|---|
| 2026-03-16 | Body height | 170 cm | 8302-2 | S |
| 2026-03-16 | Body weight | 52 kg | 29463-7 | S |
| 2026-03-16 | Body mass index (BMI) [Ratio] | 18 kg/m2 | 39156-5 | S |
| 2026-03-16 | Systolic blood pressure | 98 mm[Hg] | 8480-6 | S |
| 2026-03-16 | Diastolic blood pressure | 62 mm[Hg] | 8462-4 | S |
| 2026-03-16 | Heart rate | 92 /min | 8867-4 | S |
| 2026-03-16 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-16 | Body temperature | 37.4 Cel | 8310-5 | S |
| 2026-03-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-03-19 | Body height | 170 cm | 8302-2 | S |
| 2026-03-19 | Body weight | 51.8 kg | 29463-7 | S |
| 2026-03-19 | Body mass index (BMI) [Ratio] | 17.9 kg/m2 | 39156-5 | S |
| 2026-03-19 | Systolic blood pressure | 96 mm[Hg] | 8480-6 | S |
| 2026-03-19 | Diastolic blood pressure | 60 mm[Hg] | 8462-4 | S |
| 2026-03-19 | Heart rate | 94 /min | 8867-4 | S |
| 2026-03-19 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-03-19 | Body temperature | 37.3 Cel | 8310-5 | S |
| 2026-03-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-04-02 | Body height | 170 cm | 8302-2 | S |
| 2026-04-02 | Body weight | 53.4 kg | 29463-7 | S |
| 2026-04-02 | Body mass index (BMI) [Ratio] | 18.5 kg/m2 | 39156-5 | S |
| 2026-04-02 | Systolic blood pressure | 108 mm[Hg] | 8480-6 | S |
| 2026-04-02 | Diastolic blood pressure | 68 mm[Hg] | 8462-4 | S |
| 2026-04-02 | Heart rate | 80 /min | 8867-4 | S |
| 2026-04-02 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-04-02 | Body temperature | 36.8 Cel | 8310-5 | S |
| 2026-04-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-04-30 | Body height | 170 cm | 8302-2 | S |
| 2026-04-30 | Body weight | 55.2 kg | 29463-7 | S |
| 2026-04-30 | Body mass index (BMI) [Ratio] | 19.1 kg/m2 | 39156-5 | S |
| 2026-04-30 | Systolic blood pressure | 112 mm[Hg] | 8480-6 | S |
| 2026-04-30 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-04-30 | Heart rate | 74 /min | 8867-4 | S |
| 2026-04-30 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-04-30 | Body temperature | 36.7 Cel | 8310-5 | S |
| 2026-04-30 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-10-12 | Body height | 170 cm | 8302-2 | S |
| 2026-10-12 | Body weight | 57.2 kg | 29463-7 | S |
| 2026-10-12 | Body mass index (BMI) [Ratio] | 19.8 kg/m2 | 39156-5 | S |
| 2026-10-12 | Systolic blood pressure | 116 mm[Hg] | 8480-6 | S |
| 2026-10-12 | Diastolic blood pressure | 74 mm[Hg] | 8462-4 | S |
| 2026-10-12 | Heart rate | 68 /min | 8867-4 | S |
| 2026-10-12 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-10-12 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-10-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
| 2026-04-20 | Body height | 170 cm | 8302-2 | S |
| 2026-04-20 | Body weight | 53.6 kg | 29463-7 | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 18.5 kg/m2 | 39156-5 | S |
| 2026-04-20 | Systolic blood pressure | 104 mm[Hg] | 8480-6 | S |
| 2026-04-20 | Diastolic blood pressure | 64 mm[Hg] | 8462-4 | S |
| 2026-04-20 | Heart rate | 98 /min | 8867-4 | S |
| 2026-04-20 | Respiratory rate | 16 /min | 9279-1 | S |
| 2026-04-20 | Body temperature | 38.4 Cel | 8310-5 | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 % | 59408-5 | S |
| 2026-07-27 | Body height | 170 cm | 8302-2 | S |
| 2026-07-27 | Body weight | 56.6 kg | 29463-7 | S |
| 2026-07-27 | Body mass index (BMI) [Ratio] | 19.6 kg/m2 | 39156-5 | S |
| 2026-07-27 | Systolic blood pressure | 114 mm[Hg] | 8480-6 | S |
| 2026-07-27 | Diastolic blood pressure | 72 mm[Hg] | 8462-4 | S |
| 2026-07-27 | Heart rate | 70 /min | 8867-4 | S |
| 2026-07-27 | Respiratory rate | 14 /min | 9279-1 | S |
| 2026-07-27 | Body temperature | 36.6 Cel | 8310-5 | S |
| 2026-07-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 % | 59408-5 | S |
Social, functional, and mental status
Social history
- S Novelist; writes most mornings at a small table in the family sitting room, and revises a novel under contract; has had four novels published
- S Never married; no children; lives with her mother and her older sister in a village cottage; walks to the nearby market town for errands
- S Tobacco: never. Alcohol: a glass of wine with dinner once or twice a week. No drug use
- S Activity: walked several miles most days until this winter; now walks less because of tiredness
- S Keeps a detailed written account of her symptoms in her letters and a notebook, and brings notes to visits; prefers to make light of illness in company
- S Supports: a close bond with her sister, many nieces and nephews who write often, and work she finds absorbing
Functional status
- S Independent in all activities; tires after a short walk and needs to rest in the afternoon; has cut her writing time from full mornings to an hour or two
Mental status
- S Alert, oriented, witty and observant; describes her mood as low only because she is tired of being tired; no loss of interest or hopelessness; PHQ-9 score 6, carried by tiredness, poor appetite and poor sleep
Allergies and medications
Allergies
- S No known allergy
Medications
- S Hydrocortisone 10 mg oral tablet, one tablet by mouth on waking
- S Hydrocortisone 5 mg oral tablet, one tablet by mouth at 2 pm
- S Fludrocortisone 0.1 mg oral tablet, one tablet by mouth each morning
- S Hydrocortisone 100 mg injection kit (with diluent), 100 mg into the thigh muscle once for vomiting, collapse or signs of adrenal crisis, then call 911
- S Amoxicillin 500 mg oral capsule, one capsule by mouth twice daily for ten days
Procedures and immunizations
Procedures
- S Cosyntropin (ACTH) stimulation test, 250 mcg intravenously with cortisol at 0, 30 and 60 minutes
- S Chest X-ray, posteroanterior and lateral
- S Advance care planning conversation, about 20 minutes
Immunizations
- S 2026-07-27: Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)
- S 2026-07-27: Hepatitis B vaccine (HepB-CpG), dose 1 of 2
- S 2026-10-12: Hepatitis B vaccine (HepB-CpG), dose 2 of 2
- S 2026-10-12: Influenza vaccine, inactivated, this season
Past medical history
True biography with historical dates; not part of the synthetic care timeline.
- D 1783: Severe fever (described as putrid fever) as a young child at school, from which she nearly died (CLM-0004)
Family history
- D father: Died after an illness of only forty-eight hours; cause not recorded in the cited source
Care-plan goals
| Goal | Target date | Status | Outcome |
|---|---|---|---|
| A diagnosis within one week of the first visit, with treatment started the same day if adrenal insufficiency is confirmed | 2026-03-19 | completed | Cosyntropin test three days after the first visit; replacement started the same day |
| No adrenal crisis and no emergency admission through the episode | 2026-10-12 | completed | No crisis or admission; one febrile illness managed at home with stress dosing |
| Sodium and potassium normal, renin in the upper normal range, and no postural drop by the six-week visit | 2026-04-30 | completed | Sodium 139 and potassium 4.4 mmol/L; renin 3.4 ng/mL/h; no postural drop |
| She can state the sick-day rules and give the emergency injection by the two-week visit | 2026-04-02 | completed | Stated the rules and gave a practice injection on a trainer |
| Weight back to her usual 57 kg, and energy for full mornings of writing, by six months | 2026-10-12 | completed | Weight 57.2 kg from 52.0; writing full mornings and walking several miles |
Interventions
| Intervention | Status | Guideline |
|---|---|---|
| Initial evaluation of tiredness, weight loss, darkening skin, low sodium and high potassium: blood count, metabolic panel, thyroid tests, ferritin, vitamin B12 and folate at the first visit; urgent 8 am cortisol and ACTH with a cosyntropin stimulation test within days; until then, salt freely, and go to the emergency department at once for vomiting, fainting, confusion or severe abdominal pain | completed | GL-ES-PAI-2016, GL-CMID-2026 |
| Urgent endocrinology consultation within three days to confirm or exclude primary adrenal insufficiency, start replacement if confirmed, and plan the search for the cause | completed | GL-ES-PAI-2016 |
| Replacement: hydrocortisone 10 mg on waking and 5 mg at 2 pm (15 mg a day) and fludrocortisone 0.1 mg each morning, adjusted by weight, energy, blood pressure lying and standing, salt craving and signs of over- or under-replacement, with sodium, potassium and plasma renin after any fludrocortisone change and at least yearly | completed | GL-ES-PAI-2016 |
| Written sick-day rules (double the hydrocortisone for fever above 38 °C, triple it above 39 °C, and inject 100 mg and call 911 for vomiting, inability to take tablets, or feeling faint), an emergency hydrocortisone injection kit with training, a steroid emergency card and a medical ID, reviewed at every visit | completed | GL-ES-PAI-2016 |
| Cause and differential: 21-hydroxylase antibodies at the two-week visit; adrenal CT and tuberculosis testing only if they are negative; examination for lymph nodes and spleen, LDH and a chest X-ray now, with CT of the chest, abdomen and pelvis if weight loss, fevers, night sweats or enlarged nodes persist once replacement is established | completed | GL-ES-PAI-2016 |
| Screening for associated autoimmune disease: TSH (normal at intake) at least yearly; vitamin B12, A1c, and celiac serology with total IgA; ask about periods at each visit and check FSH if they become irregular or stop | completed | GL-ES-PAI-2016, GL-ACG-CD-2023 |
| Anemia: ferritin, vitamin B12 and folate at intake; repeat the blood count on treatment and look further only if it does not recover | completed | GL-CMID-2026 |
| Streptococcal pharyngitis: amoxicillin 500 mg twice daily for ten days; hydrocortisone doubled under the sick-day rules until a day without fever and then back to the usual dose; fluids with salt; the emergency injection with a 911 call if she vomits or cannot take tablets; neck nodes rechecked at the six-week visit | completed | GL-ES-PAI-2016, GL-IDSA-GAS-2012 |
Planned encounters
- 2026-03-16 — New patient visit for about three months of tiredness, weight loss, darkening skin, nausea and back ache, with blood tests and urgent endocrinology referral (ENC-001)
- 2026-03-19 — Endocrinology consultation with a cosyntropin stimulation test, diagnosis, and start of replacement (ENC-002)
- 2026-04-02 — Two-week review after starting replacement: electrolytes, cause, and autoimmune screening (ENC-003)
- 2026-04-20 — Same-day sick visit for streptococcal pharyngitis with stress dosing of hydrocortisone (ENC-006, unscheduled)
- 2026-04-30 — Six-week review: electrolytes, renin, blood count, and recovery (ENC-004)
- 2026-07-27 — Periodic adult preventive visit (ENC-007)
- 2026-10-12 — Seven-month review: replacement, renin, thyroid, mood, and the closing of the differential (ENC-005)
Supporting documents
- History and physical
- Progress note 01
- Progress note 02 — Focused Visit (Follow-up)
- Progress note 03 — Focused Visit (Follow-up)
- Progress note 04 — Sick Visit
- Progress note 05 — Focused Visit (Follow-up)
- Progress note 06 — Preventive Visit
- Progress note 07 — Focused Visit (Care-plan review)
- Endocrinology referral
- Endocrinology consultation
- Patient care plan
- Teaching note
- Provenance CSV
C-CDA note documents
Each link opens a readable copy; the XML beside it is the exchange file.
- History and physical (XML)
- Progress note 01 (XML)
- Progress note 02 — Focused Visit (Follow-up) (XML)
- Progress note 03 — Focused Visit (Follow-up) (XML)
- Progress note 04 — Sick Visit (XML)
- Progress note 05 — Focused Visit (Follow-up) (XML)
- Progress note 06 — Preventive Visit (XML)
- Progress note 07 — Focused Visit (Care-plan review) (XML)
- Endocrinology referral (XML)
- Endocrinology consultation (XML)
Sources
Review status
| Review | Status | Notes |
|---|---|---|
| schema validation | not_started | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | Awaiting clinician review; check the three-day interval to the cosyntropin test in a stable outpatient, the hydrocortisone and fludrocortisone doses, the sick-day rules, and how lymphoma and tuberculosis are kept in and then out of the differential. |
| provenance review | not_started | The Jane Austen Society biography, the 1913 Family Record and the 1892 letters (Project Gutenberg), the British Library blog, and four PubMed records (three abstracts read) logged. Cope's 1964 article could not be read and is described through the Upfal and White abstracts. Le Faye's edition of the letters was not consulted. |
| safe messaging review | not_started | No sensitive claims. Her death is recorded as history in one sentence. The modern diagnosis is presented as one possibility, not as the cause of her real illness. |
Comments and corrections
Sign in with GitHub to comment on this record. To report a specific error, ideally with a source, use the feedback form; each report becomes a tracked issue.
Comments appear on the online version of this page.